

Focus on Faculty #10

Thierry Alcindor



[Dr. Thierry Alcindor](#) was born and raised in Port-au-Prince, Haiti. After obtaining his medical degree at Université d'État d'Haïti, he spent two and a half years at the Albert Schweitzer Hospital as a Social Medicine resident in the central Artibonite region of the country. He then decided to specialize in North America, undertaking his Internal Medicine residency and Hematology/Oncology fellowship at Yale-New Haven Medical Center and Tufts-New England Medical Center, respectively. Brigham and Women's Hospital and the Mayo Clinic were sites of complementary training.

After his training, Dr. Alcindor was offered a position of Assistant Professor of Medicine (Hematology/Oncology) at the University of Sherbrooke where he spent three years. He then moved to McGill University where he is currently Associate Professor of Oncology and Medicine. He has been based at the MUHC since 2004, devoting his practice and research efforts to the care of patients with digestive cancers and sarcomas. With the support of the Cedars Cancer Foundation and of the MUHC Department of Oncology, he obtained a Master's degree in Experimental Therapeutics at the University of Oxford.

Dr. Alcindor's clinical research portfolio includes investigator-initiated studies, as well as trials with pharmaceutical companies and oncology cooperative groups. He is the co-chair of the Sarcoma Disease Site Committee at NCIC CTG (now called Canadian Cancer Trials Group or CCTG) and has led several studies as a national principal investigator. He has also played the role of member of the Data Safety Monitoring Committee for the French Sarcoma Group and member of the International Management Committee of trials for the Australasian Gastrointestinal Trials Group. He was selected Clinical Lead for the Gastrointestinal Disease Site of the Rossy Cancer Network and is currently Interim Director of the MUHC Division of Medical Oncology and Associate Director for Clinical Trials in Oncology at the Centre for Innovative Medicine (Research Institute of the MUHC).

When not busy with work, Dr. Alcindor enjoys reading (fiction literature and Haitian history), listening to music (especially opera and soul music), and traveling with his wife and his daughter.

We asked Dr. Alcindor to list a few of his articles whose work he is particularly proud or enjoyed the most. This is what he provided:

Alcindor T: Activity of paclitaxel in metastatic anal squamous cell carcinoma. *International Journal of Colorectal Disease*. 2008 Jul; 23(7): 717. Epub 2008 Mar 12 (high-impact case series)

Ferri LE, Ades S, **Alcindor T**, Chasen M, Hickeson M, Artho G, Marcus V, Thirlwell MP. Peri-Operative Docetaxel, Cisplatin, and 5-Flourouracil (DCF) for Locally Advanced Esophageal and Gastric Adenocarcinoma: Safety and Response Results from a Multi-Center Phase II Trial. *Annals of Oncology*. 2012 Jun; 23(6):1512-7. doi: 10.1093/annonc/mdr465. Epub 2011 Oct 29 (McGill-based clinical trial)

Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, **Alcindor T**, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PCW, Paolo dei Tos A, van der Graaf W. Single agent doxorubicin versus intensified doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma: A randomised Phase III trial by the European Organisation and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). *Lancet Oncology* doi: 10.1016/S1470-2045(14)70063-4. March 2014 [Epub ahead of print] (fruitful international collaboration)